GLP-1, Fasting Insulin & HOMA-IR: Insulin Resistance

Fasting insulin and HOMA-IR (a calculation from fasting glucose × fasting insulin) are the everyday markers of insulin resistance — the core metabolic problem behind type 2 diabetes, PCOS, fatty liver, and much obesity-related disease. On a GLP-1 they generally improve: in the STEP 1 trial, semaglutide reduced fasting serum insulin and HOMA-IR versus placebo (Kosiborod 2023 ^[1]), and other randomized data show the same direction (Anyiam 2024 ^[2]; Arslanian 2026 ^[3]). The improvement is driven mostly by weight loss, with help from the drug's glucose-dependent action on the pancreas. A falling fasting insulin / HOMA-IR is one of the most encouraging things to watch — it means your body is becoming more sensitive to its own insulin. Here's what the numbers mean and their limits.

The honest summary

• Fasting insulin and HOMA-IR usually fall. In STEP 1, semaglutide significantly reduced fasting serum insulin and HOMA-IR versus placebo (Kosiborod 2023^[1]) — a sign of improving insulin sensitivity.
• It tracks with weight loss. Insulin resistance is tightly linked to body fat (especially visceral and liver fat); GLP-1 weight loss is the main driver of the improvement.
• The drug also acts on the pancreas — glucose-dependently. GLP-1 enhances insulin secretion only when glucose is elevated, which is why it improves glycemic control without causing low blood sugar on its own.
• Consistent across populations. Improvements in insulin sensitivity show up in adults (Anyiam 2024^[2]) and adolescents (STEP TEENS, Arslanian 2026^[3]).
• HOMA-IR is a useful trend marker, not a precise gauge. It's an estimate; single values bounce around, and it isn't validated for people already on insulin. Watch the direction over time, with your clinician.

What fasting insulin and HOMA-IR actually measure

When you're insulin resistant, your tissues respond poorly to insulin, so the pancreas pumps out more of it to keep glucose in range. That shows up as a high fasting insulin even when fasting glucose still looks normal — which is why fasting insulin can flag a problem years before blood sugar does. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) combines fasting glucose and fasting insulin into a single number estimating that resistance. As insulin sensitivity improves, the pancreas can do the same job with less insulin, so fasting insulin and HOMA-IR both come down. That downward move is the metabolic signal you want.

What the trials show

Kosiborod 2023^[1] examined cardiometabolic risk factors in STEP 1 and STEP 4 (once-weekly semaglutide 2.4 mg in overweight/obesity without diabetes). In STEP 1, reductions in fasting serum insulin and HOMA-IR — alongside waist circumference, blood pressure, fasting glucose, and lipids — were significantly greater with semaglutide than placebo. Anyiam 2024^[2] (Clinical Nutrition) compared the metabolic effects of a very-low-calorie diet, semaglutide, or both in type 2 diabetes and likewise documented improved insulin/metabolic measures. And in adolescents, the STEP TEENS analysis (Arslanian 2026^[3], Diabetes Care) reported improved insulin sensitivity and cardiometabolic risk factors with semaglutide. The throughline: as weight and fat fall, the body needs less insulin to manage glucose.

The limits of these markers

HOMA-IR is an estimate, not a gold-standard measurement (that would be a research-grade clamp study). Practical caveats: a single fasting insulin can vary with stress, recent meals, and lab assay, so one reading means little — the trend is what matters. HOMA-IR is not valid in people already taking insulin (exogenous insulin distorts the calculation), and it's less reliable in advanced beta-cell failure. Fasting insulin also isn't a routine screening test everywhere, and reference ranges vary by lab. Use these as a direction-of-travel marker your clinician interprets in context — not a number to fixate on or self-diagnose from.

What to do with your numbers

• Fasting insulin / HOMA-IR trending down: favorable — your insulin sensitivity is improving as you lose weight. Track the trend at follow-up.
• Single high or odd value: don't over-read it — repeat in context; these markers are noisy.
• On insulin therapy: HOMA-IR isn't valid for you; your clinician will judge insulin sensitivity differently (and may be reducing your insulin dose as the GLP-1 helps).
• PCOS or fatty liver: improving insulin resistance is central to both — a falling HOMA-IR is a meaningful marker of progress beyond weight alone.

Bottom line

GLP-1 therapy lowers fasting insulin and improves HOMA-IR^[1][2][3], reflecting better insulin sensitivity — the metabolic root issue behind type 2 diabetes, PCOS, and fatty liver. It's driven mostly by weight loss, with the drug's glucose-dependent pancreatic effect on top. Treat these as encouraging trend markers, not precise gauges (and not valid if you're on insulin), and interpret the direction over time with your clinician.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed trial analysis indexed in PubMed, verified against the live PubMed database before publication. Interpret metabolic labs with your own clinician.